SecBot SecBot
Biotech Drug Report Generated Jul 13, 2026

ERAS-4001

ERAS·Erasca, Inc.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 1/1b
Time to market
5+ years; still in Phase 1/1b first-in-human testing with no registration-enabling plans announced yet
Why 6/10
Preliminary Phase 1 monotherapy data from the BOREALIS-1 trial is expected in H2 2026. This is a dated binary within ~6 months on an asset that is a meaningful but not sole value driver (Erasca also has lead program ERAS-0015 with positive Phase 1 data). Phase 1 readouts typically move stocks 20-50% for early-stage biotechs with robust preclinical data, but the stock's recent run (from ~$1.33 to ~$18) already reflects high expectations.
Actionable Insight NEUTRAL

Watch for Erasca's H2 2026 BOREALIS-1 preliminary data release. ERAS-4001 is a "second shot on goal" after ERAS-0015's strong Phase 1 showing in April 2026. The stock already trades near analyst mean PT of $21 with a massive run-up from 52-week lows, so upside may be partially priced in. The key question is whether early safety/efficacy data can differentiate ERAS-4001 from Revolution Medicines' daraxonrasib (RMC-6236, Phase 3).

Price Chart

Loading chart...

Executive Summary

ERAS-4001 is a preclinical-stage-to-Phase 1 oral pan-KRAS inhibitor being developed by Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers. In-licensed from Medshine Discovery in 2024, the drug targets the KRAS protein, one of the most important drivers of human cancer, while sparing HRAS and NRAS, which could give it a tolerability edge over broader pan-RAS inhibitors. The BOREALIS-1 Phase 1 trial is actively enrolling, and initial monotherapy data is expected in the second half of 2026. Erasca has a strong cash runway ($408.5M into H2 2028) and deep institutional backing (BlackRock, RTW, Vanguard top holders). However, ERAS-4001 faces intense competition from Revolution Medicines' Phase 3 pan-RAS inhibitor daraxonrasib and approved KRAS G12C drugs from Amgen and BMS/Mirati. The stock has rallied dramatically from $1.33 to ~$18 year-to-date, partially reflecting optimism around the broader pipeline.

How It Works

ERAS-4001 is an oral pill designed to block a cancer-driving protein called KRAS. KRAS is mutated in roughly 25% of all human cancers and acts like a stuck "on" switch that tells cancer cells to grow uncontrollably. Unlike older drugs that target only one specific KRAS mutation (e.g., G12C), ERAS-4001 is a "pan-KRAS" inhibitor, it blocks multiple different mutant forms of KRAS as well as normal (wildtype) KRAS, while purposefully sparing two related proteins HRAS and NRAS. This selectivity is intended to give a wider therapeutic window (fewer side effects) versus broader "pan-RAS" inhibitors.

Trial Status

BOREALIS-1 Phase 1/1b first-in-human trial (NCT07021898) is actively recruiting patients with KRAS-mutant advanced solid tumors. Dose escalation is ongoing as monotherapy, with plans for combination dose-escalation and monotherapy expansion cohorts in 2027. Preliminary Phase 1 monotherapy safety, tolerability, PK, and initial efficacy data expected H2 2026. Preclinical data presented at AACR 2025 showed potent anti-tumor activity with single-digit nanomolar potency against KRAS G12X mutants while sparing HRAS and NRAS.

The Two-Sided Case

▲ Bull Case6
Potential first-in-class and best-in-class profile: ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor that spares HRAS and NRAS, potentially offering a superior therapeutic window over broader pan-RAS inhibitors (source: erasca.com press release).
Massive addressable market: RAS/MAPK pathway mutations occur in over 30% of all human cancers, a multi-billion-dollar TAM with significant unmet need (source: koalagains.com analysis).
Strong cash runway: $408.5M in cash as of Q1 2026 funds operations into H2 2028, reducing near-term dilution risk (source: Erasca Q1 2026 press release).
Deep institutional backing: BlackRock (20.1M shares), RTW Investments (16.2M), Vanguard (11.2M) and State Street (9.3M) are top holders.
Strong analyst consensus: 14 analysts rate ERAS with 5 Strong Buy and 9 Buy ratings (0 Sell); mean price target $21, range $12-$30, with several firms raising targets in 2026.
Preclinical data supports selectivity thesis: AACR 2025 data showed potent KRAS G12X inhibition with sparing of HRAS/NRAS, potentially limiting wildtype-mediated off-target toxicity (source: erasca.com AACR 2025 poster).
▼ Bear Case6
Extremely early stage: ERAS-4001 is in Phase 1 first-in-human testing, no efficacy data in patients yet. Most early-stage oncology drugs fail before reaching registration trials (source: ClinicalTrials.gov NCT07021898).
Intense competition: Revolution Medicines' daraxonrasib (RMC-6236) is already in Phase 3 for pancreatic cancer with median PFS of 8.5-8.8 months, and approved KRAS G12C drugs (Amgen's Lumakras, BMS's Krazati) are on the market (source: fiercebiotech.com, ainvest.com).
In-licensed, not internally discovered: ERAS-4001 was in-licensed from Medshine Discovery. Erasca laid off 18% of staff to make room for this program, raising questions about internal R&D capabilities (source: fiercebiotech.com).
Massive stock appreciation already priced in: ERAS has rallied from a 52-week low of $1.33 to ~$18, a 13x+ increase. The current price already sits near the $21 mean analyst target, limiting further upside.
Pipeline concentration risk: While ERAS-4001 is one of several programs, the company is heavily RAS-focused. Any setback in this program or the lead ERAS-0015 could severely impact the stock (source: simplywall.st analysis).
Q1 2026 net loss of $183.4M was significant, though partly driven by a $150M one-time IP R&D expense for the ERAS-0015 global expansion license (source: Erasca Q1 2026 earnings).

Upcoming Catalysts

  • Preliminary Phase 1 monotherapy data for ERAS-4001 (BOREALIS-1 trial) expected H2 2026, the next major catalyst
  • Monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027
  • ERAS-0015 (lead program) registration-enabling trial in lung cancer expected H1 2027 and Phase 3 pancreatic cancer trial in 2027, these readouts will also move ERAS stock

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Erasca, Inc. Press Release ERAS ·Originating report

Sources · 13

Hover a chip for the title
1 erasca.com2 erasca.com3 stocktitan.net4 clinicaltrials.gov5 erasca.com6 erasca.com7 oncologypipeline.com8 fiercebiotech.com9 koalagains.com10 investors.erasca.com11 synapse.patsnap.com12 koalagains.com13 fiercebiotech.com